Troy Wilson, Kura Oncology CEO

Ku­ra On­col­o­gy se­cures up to $150M in Bris­tol My­ers eq­ui­ty in­vest­ment, loan from Her­cules Cap­i­tal

Ku­ra On­col­o­gy is set for a few more years, thanks to some new part­ners.

The pub­lic on­col­o­gy biotech put out word last week that it brought in some more fund­ing — which, if maxed out, will ex­tend its run­way in­to 2026. The first amount of fi­nanc­ing is from Bris­tol My­ers, which is in­vest­ing $25 mil­lion in­to the biotech as an eq­ui­ty in­vest­ment. The sec­ond, more sub­stan­tial fi­nanc­ing is in the form of a term loan fa­cil­i­ty worth $125 mil­lion from Her­cules Cap­i­tal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.